What Happened

Immunis, Inc., a biotechnology company focused on age-related diseases, announced on June 19, 2026, that it has successfully secured $12 million in a Series A funding round. This capital injection is earmarked to further the development of its stem cell-derived biologics.

The funding will support ongoing clinical trials and research initiatives. This financial boost positions Immunis, Inc. to accelerate its mission in addressing significant unmet medical needs within the aging population.

Who Is Immunis, Inc.

Founded in 2019, Immunis, Inc. is a private, clinical-stage biotechnology company based in the United States. It specializes in developing innovative therapeutic solutions for age-related diseases and immune dysfunction.

The company's core focus is on leveraging stem cell-derived biologics, specifically secretomes, to modulate immune responses. Immunis aims to improve health outcomes for conditions such as age-related muscle wasting (sarcopenia) and neurodegenerative disorders.

What Does Immunis, Inc. Do

Immunis, Inc. develops investigational secretomes, such as IMM01-STEM, which are designed to refine immune cell responses. These biologics contain a balance of natural, clinical-grade factors that support immune system development, modulation, and overall health.

Their product, IMM01-STEM, has shown promising preclinical results in muscle regeneration, mass, and function. It has also demonstrated the ability to increase whole-body lean mass and reduce fat mass, addressing critical aspects of age-related decline.

The company is currently conducting a Phase 2 clinical trial for IMM01-STEM, targeting patients with sarcopenic obesity. This trial investigates the safety and efficacy of their therapy in simultaneously decreasing fat and enhancing muscle, a significant challenge in an aging population.

Healthcare & Biotech Market Context

The healthcare and biotech sector is experiencing significant investment, particularly in areas addressing age-related conditions and chronic diseases. An aging global population is driving demand for innovative therapies that improve quality of life and extend healthy lifespans.

Companies developing advanced biologics and regenerative medicine solutions are attracting substantial capital. The focus on stem cell therapies and secretomes represents a cutting-edge segment within this market, promising novel approaches to complex health issues.

Regulatory pathways for these advanced therapies are also evolving, creating both opportunities and challenges for biotech firms. The potential for high impact on patient outcomes continues to fuel investor interest in this specialized field.

Why This Matters

This funding round is a strong indicator of investor confidence in Immunis, Inc.'s platform and its potential to disrupt the age-related disease market. The $12 million will be crucial for advancing their clinical pipeline and bringing IMM01-STEM closer to market.

The successful progression of their Phase 2 trial could position Immunis, Inc. as a key player in sarcopenia and obesity treatment. This puts Immunis, Inc. in closer competition with established pharmaceutical companies developing muscle-wasting treatments, such as Regeneron Pharmaceuticals, in the regenerative medicine market.

For B2B vendors, this funding signifies an opportunity to engage with a growing biotech firm. Immunis, Inc. will likely be investing in advanced laboratory equipment, clinical trial management software, and specialized research services to support its expanded operations.

What to Watch

In the next 6-12 months, we can expect Immunis, Inc. to focus heavily on the outcomes of its ongoing Phase 2 clinical trial for IMM01-STEM. Positive results would likely lead to further funding rounds and potentially expanded clinical programs. The company may also look to scale its research and development teams, indicating potential hiring opportunities.